Yusuke Nakamura to Antiviral Agents
This is a "connection" page, showing publications Yusuke Nakamura has written about Antiviral Agents.
Connection Strength
1.039
-
Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. J Gen Virol. 2013 Jan; 94(Pt 1):81-89.
Score: 0.082
-
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012; 55(6):417-25.
Score: 0.080
-
Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J Infect Dis. 2012 Jan 15; 205(2):204-10.
Score: 0.078
-
Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011 Sep 02; 54(3):764-71.
Score: 0.076
-
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012; 55(3):231-41.
Score: 0.075
-
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2011 Jun; 83(6):981-8.
Score: 0.075
-
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011 Jun; 83(6):1048-57.
Score: 0.075
-
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011 Jun; 54(6):1094-101.
Score: 0.073
-
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011 May; 92(Pt 5):1071-1081.
Score: 0.073
-
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011 Feb; 60(2):261-7.
Score: 0.072
-
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010 Aug; 52(2):421-9.
Score: 0.071
-
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct; 139(4):1190-7.
Score: 0.071
-
A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology. 2009 May; 136(5):1796-805.e6.
Score: 0.064
-
Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol. 2011 Sep; 83(9):1597-607.
Score: 0.019
-
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011 Jul 01; 204(1):84-93.
Score: 0.019
-
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011 Feb; 53(2):415-21.
Score: 0.018
-
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011 Mar; 54(3):408-14.
Score: 0.018